Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.63 |
| ▸ | TTR | P02766 | 1/20 | 0.63 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | ABCB1 | P08183 | 12/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.53 |
| ▸ | DHODH | Q02127 | 1/20 | 0.53 |
| ▸ | MGAM | O43451 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4834251 | 1.00 | PDPK1 (0.63) | PDPK1TTRALOX5MEN1LMNA | |
| SCHEMBL143839 | 0.90 | PDPK1 (0.69) | PDPK1TTRALOX5MEN1LMNA | |
| SCHEMBL12961706 | 0.82 | PDPK1 (0.61) | PDPK1TTRALOX5MEN1LMNA | |
| SCHEMBL144848 | 0.78 | ABCB1 (0.85) | PDPK1TTRALOX5MEN1LMNA | |
| Xanthogalenol SCHEMBL4837290 | 0.78 | PDPK1 (0.84) | PDPK1TTRALOX5MEN1LMNA | |
| Xanthohumol SCHEMBL30169731 | 0.78 | PDPK1 (1.00) | PDPK1TTRALOX5MEN1LMNA | |
| Xanthohumol SCHEMBL143683 | 0.78 | PDPK1 (1.00) | PDPK1TTRALOX5MEN1LMNA | |
| Xanthohumol SCHEMBL738122 | 0.78 | PDPK1 (1.00) | PDPK1TTRALOX5MEN1LMNA | |
| Xanthogalenol SCHEMBL30259154 | 0.78 | PDPK1 (0.84) | PDPK1TTRALOX5MEN1LMNA | |
| Xanthogalenol SCHEMBL4837282 | 0.78 | PDPK1 (0.84) | PDPK1TTRALOX5MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7326734-B2 | Treatment of bladder and urinary tract cancers | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-02-05 | — | — | US | disclosed |
| US-20040259813-A1 | Treatment of bladder and urinary tract cancers | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259813-A1 | Treatment of bladder and urinary tract cancers | KLK5, KLK4, KLK6 | PDPK1 279/4885TTR 1993/4885ALOX5 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.